Bristol Myers Squibb-Pfizer Alliance Announce New Direct-To-Patient Option For Purchasing Eliquis Via Alliance's Patient Resource Eliquis 360 Support

+2.36% Pre

+0.19% Pre

Bristol-Myers Squibb Company

BMY

52.41

52.80

+2.36%

+0.74% Pre

Pfizer Inc.

PFE

25.85

25.93

+0.19%

+0.31% Pre

Eliquis 360 Support Program Now Offers Eliquis to Cash-Paying Patients at More than 40% Discount to Current List Price

The Bristol Myers Squibb-Pfizer (NYSE:BMY) – (NYSE:PFE) Alliance today announced a new direct-to-patient option for purchasing Eliquis®(apixaban) via our Alliance's patient resource Eliquis 360 Support. The offering provides an opportunity for uninsured, underinsured, or self-pay patients to significantly lower their out-of-pocket costs for this critical medicine. Eliquis is relied upon by millions of Americans daily and this program will provide a simple and transparent way to access it.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.